NIM
IOVA icon

NEOS Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

NEOS Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-173,872
Closed -$377K – 661
2025
Q3 		$377K Buy
+173,872
New +$411K ﹤0.01% 598

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NEOS Investment Management's IOVA Position: Q4 2025 in Review

NEOS Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 173,872 shares — an estimated $377K sold.

NEOS Investment Management first reported a position in IOVA in Q3 2025 and held it in 1 quarter. The position peaked at $377K in Q3 2025. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • NEOS Investment Management reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • NEOS Investment Management sold 173,872 Iovance Biotherapeutics shares in Q4 2025, an estimated $377K.
  • NEOS Investment Management first reported a position in Iovance Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • NEOS Investment Management's Iovance Biotherapeutics position peaked at $377K in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on NEOS Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.